Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program

Safety and antitumor activity of selinexor (KPT-330), a first-in-class, oral XPO1 selective inhibitor of nuclear export: A phase I study expanded with colon cancer cohort.

(2017) Morten Mau-Soerensen et al.   JOURNAL OF CLINICAL ONCOLOGY

Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing

(2015) Jasper E. Neggers et al.   CHEMISTRY & BIOLOGY

Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer

(2015) Jiankun Gao et al.   Oncotarget

SWI/SNF chromatin remodeling complexes and cancer

(2014) Jaclyn A. Biegel et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS

The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells

(2014) J. Zhang et al.   BLOOD

247 Selective inhibitors of nuclear export (SINE) block the expression of DNA damage repair proteins and sensitize cancer cells to DNA damage therapeutic agents

(2014) T. Kashyap et al.   EUROPEAN JOURNAL OF CANCER

Recommendations for Analyzing and ReportingTP53Gene Variants in the High-Throughput Sequencing Era

(2014) Thierry Soussi et al.   HUMAN MUTATION

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program:PALB2mutation predicts exceptionalin vivoresponse to BMN 673

(2014) Malcolm A. Smith et al.   PEDIATRIC BLOOD & CANCER

Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study

(2014) Cheryl A. London et al.   PLoS One

Clinical translation of nuclear export inhibitors in cancer

(2014) William T. Senapedis et al.   SEMINARS IN CANCER BIOLOGY

The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes

(2014) Robert Huether et al.   Nature Communications

Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib

(2014) N. Wagle et al.   Cancer Discovery

KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia

(2013) Julia Etchin et al.   BRITISH JOURNAL OF HAEMATOLOGY

Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas

(2013) A. S. Azmi et al.   HAEMATOLOGICA

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

(2013) J Schmidt et al.   LEUKEMIA

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

(2013) Y-T Tai et al.   LEUKEMIA

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program

(2013) Hernan Carol et al.   PEDIATRIC BLOOD & CANCER

Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1

(2013) Qingxiang Sun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia

(2012) P. Ranganathan et al.   BLOOD

Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma

(2012) Kejie Zhang et al.   EXPERIMENTAL HEMATOLOGY

Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors

(2012) Ori Kalid et al.   JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

Inhibition of CRM1-Mediated Nucleocytoplasmic Transport: Triggering Human Melanoma Cell Apoptosis by Perturbing Multiple Cellular Pathways

(2012) Gaurav Pathria et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The genetic landscape of mutations in Burkitt lymphoma

(2012) Cassandra Love et al.   NATURE GENETICS

Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program

(2012) Hernan Carol et al.   PEDIATRIC BLOOD & CANCER

Genome Sequencing Identifies a Basis for Everolimus Sensitivity

(2012) G. Iyer et al.   SCIENCE

SCF-Mediated Degradation of p100 (NF- B2): Mechanisms and Relevance in Multiple Myeloma

(2012) L. Busino et al.   Science Signaling

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

(2011) Peter J. Houghton et al.   PEDIATRIC BLOOD & CANCER

Regulation of the tumour suppressor Fbw7α by PKC-dependent phosphorylation and cancer-associated mutations

(2010) Joanne Durgan et al.   BIOCHEMICAL JOURNAL

Subtype-Specific FBXW7 Mutation and MYCN Copy Number Gain in Wilms' Tumor

(2010) R. D. Williams et al.   CLINICAL CANCER RESEARCH

National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testing

(2010) Min H. Kang et al.   PEDIATRIC BLOOD & CANCER

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program

(2010) E. Anders Kolb et al.   PEDIATRIC BLOOD & CANCER

EXPRESSION OF CRM1 IN HUMAN GLIOMAS AND ITS SIGNIFICANCE IN P27 EXPRESSION AND CLINICAL PROGNOSIS

(2009) Aiguo Shen et al.   NEUROSURGERY

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program

(2009) Richard Gorlick et al.   PEDIATRIC BLOOD & CANCER

The Karyopherin proteins, Crm1 and Karyopherin β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation

(2008) Pauline J. van der Watt et al.   INTERNATIONAL JOURNAL OF CANCER

Initial testing of cisplatin by the pediatric preclinical testing program

(2007) Mimi Tajbakhsh et al.   PEDIATRIC BLOOD & CANCER